U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,788.10
    -23.10 (-1.28%)
     
  • Silver

    22.64
    -0.81 (-3.44%)
     
  • EUR/USD

    1.1970
    +0.0057 (+0.4788%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.3169%)
     
  • USD/JPY

    104.0500
    -0.2000 (-0.1918%)
     
  • BTC-USD

    16,953.01
    -232.34 (-1.35%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

Bernstein Analyst Shares His Picks In Biopharma Sector

Craig Jones
·1 min read

Ronny Gal of Bernstein spoke on CNBC's "The Exchange" about stocks he likes in the biopharmaceutical sector. He thinks we can shrug off the political risk as it seems unlikely Democrats would be able to pass a resolution that could hurt the sector.

In the sector, he likes Pfizer Inc. (NYSE: PFE) as he doesn't see any material downside in the near term for the stock.

Gal also likes AbbVie Inc (NYSE: ABBV). He explained that the big fear is related to its Humira drug because it's losing its patent protection. He believes there are a couple of good drugs in AbbVie's pipeline that could prove to be a great substitute for the lost revenue from Humira. He also likes the Allergan acquisition because he thinks it's going to come back roaring.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.